Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SOLIGENIX, INC. Director's Dealing 2010

Jun 21, 2010

35119_dirs_2010-06-21_21973a30-ec40-4353-92da-3ce289f09a91.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SOLIGENIX, INC. (SNGX)
CIK: 0000812796
Period of Report: 2010-06-18

Reporting Person: SIGMA TAU FINANZIARIA SPA (10% Owner)
Reporting Person: SIGMA TAU INTERNATIONAL SA (10% Owner)
Reporting Person: Sigma-Tau America S.A. (10% Owner)
Reporting Person: Sigma-Tau Pharmaceuticals, Inc. (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2010-06-18 Common Stock P 8608580 $0.205 Acquired 54227816 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2010-06-18 Common Stock Warrant (right to buy) $0.28 J 1 Acquired 2015-06-18 Common Stock (5165148) Indirect

Footnotes

F1: Shares directly owned by Sigma-Tau Pharmaceuticals, Inc. ("Pharmaceuticals"). Pharmaceuticals is a direct wholly-owned subsidiary of Sigma-Tau America S.A. ("America"). America is a direct wholly-owned subsidiary of Sigma-Tau International S.A. ("International"). International is a direct wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A.

F2: This warrant was issued by the Issuer to Pharmaceuticals in consideration of Pharmaceuticals' purchase of 8,608,580 shares of common stock on June 18, 2010.

F3: The expiration date of the warrant may be accelerated at the Issuer's option if the Issuers's common stock meets certain price thresholds and the common shares underlying the warrant are registered for resale pursuant to an effective registration statement or are freely transferable without volume restrictions pursuant to Rule 144 under the Securities Act of 1933, as amended.